Soleus Capital Management L.P. Buys 141,400 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Soleus Capital Management L.P. grew its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 65.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 358,379 shares of the company's stock after purchasing an additional 141,400 shares during the quarter. Krystal Biotech comprises approximately 3.5% of Soleus Capital Management L.P.'s portfolio, making the stock its 5th largest holding. Soleus Capital Management L.P. owned approximately 1.25% of Krystal Biotech worth $56,144,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Norges Bank purchased a new position in Krystal Biotech during the fourth quarter worth approximately $34,391,000. Raymond James Financial Inc. acquired a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $15,989,000. Price T Rowe Associates Inc. MD raised its position in shares of Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after buying an additional 71,200 shares during the period. Integral Health Asset Management LLC purchased a new position in Krystal Biotech in the fourth quarter worth approximately $8,616,000. Finally, TimesSquare Capital Management LLC increased its stake in Krystal Biotech by 39.1% during the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock worth $24,888,000 after acquiring an additional 44,646 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Down 1.1%

NASDAQ KRYS traded down $1.39 during trading on Thursday, hitting $125.29. The stock had a trading volume of 470,248 shares, compared to its average volume of 307,433. The company has a market capitalization of $3.62 billion, a PE ratio of 41.90 and a beta of 0.79. Krystal Biotech, Inc. has a twelve month low of $125.04 and a twelve month high of $219.34. The firm has a 50 day moving average price of $163.85 and a 200 day moving average price of $167.69.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright restated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 6th. Citigroup lowered their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research note on Friday, May 16th. Guggenheim reduced their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, Chardan Capital restated a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $211.13.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).